The Effect of Inspiratory Muscle Training on Cognitive Functions, Cerebral Oxygenation, and Neurotrophic Factor Level in Patients With Obstructive Sleep Apnea Syndrome
NCT07329049, Not applicable, Not yet recruiting, Istinye University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Inspiratory Muscle Training on Cognitive Functions, Cerebral Oxygenation, and Neurotrophic Factor Level in Patients With Obstructive Sleep Apnea Syndrome | ClinicalTrials.gov |
| NCT number | NCT07329049 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 42 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Istinye University | ClinicalTrials.gov |
| Conditions | Obstructive Sleep Apnea Syndrome (OSAS) | ClinicalTrials.gov |
| Interventions | inspiratory muscle training, Placebo inspiratory muscle training, Usual Care | ClinicalTrials.gov |
| First posted | 2026-01-09 | ClinicalTrials.gov |
| Last updated | 2026-01-09 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Digit Span Test | Baseline and 8 weeks | A subscale of the WAIS-R, this test aims to measure an individual's level of attention. It is administered in two parts using forward and backward sequencing of numbers. Numbers between 1 and 9 are presented to the individual in a random order, and the individual is asked to repeat them in the same sequence. The test is repeated until the individual correctly repeats the sequence twice in a row or until 12 repetitions are reached. In the evaluation of the test, 2 points are awarded for each correct sequence and 1 point for each sequence with one error. Since there are a total of 12 attempts, even if the individual correctly repeats the sequence twice, 2 points are added for each additional attempt required to reach 12 attempts. The maximum possible score on the test is 24. The test will be administered on the first and last days of treatment. | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment Scale | Baseline and 8 weeks | The Turkish version will be used to assess individuals' cognitive function. This scale, which takes approximately 10 minutes to administer, will be administered face-to-face with individuals. The maximum score that can be obtained on the scale is 30. One point is added for individuals with less than 12 years of education. The cutoff value for the scale has been set at \<23. The MBDÖ assesses 8 different cognitive function areas: memory, executive functions, visual construction skills, concentration, language, orientation, calculation, and attention. The first and last days of treatment will be evaluated. | ClinicalTrials.gov |
| Primary | Oktem Verbal Memory Processes Test | Baseline and 8 weeks | The Turkish adaptation of the Verbal Memory Processes Test, developed by Rey in 1964, was created by Oget Oktem.It assesses verbal memory processes such as auditory-verbal learning, memory recording, recall, and recognition.There is a recognition list with 15 words on the front and 45 words on the back.The target word list on the front is repeated 10 times, and after each repetition, the individual is asked to say the words they have learned, which are recorded, and their score is tallied.This score is the Learning Score Dimension. After a 30-40 minute interval, the individual is asked to recall the target words.The score obtained here is the Spontaneous Recall Dimension score. For words that cannot be recalled, three recognition words consisting of one phonemic and one semantic distractor from the recognition list on the back side will be read, and then the individual will be asked whether the word is found in the target word list.The score obtained is the Recognit Dimension Score. | ClinicalTrials.gov |
| Primary | Stroop Test | Baseline and 8 weeks | This test measures the ability to inhibit inappropriate responses in executive functions, provides information about selective attention under distracting conditions, and demonstrates frontal lobe functions in the brain.Before starting the test, the person is taught which buttons to press for 4 colors (1=yellow, 2=blue, 3=green, and 4=red).Then, the three-stage test begins: In the first stage, the person must identify the color of 24 colored circles appearing sequentially on the screen and press the correct key.In the second stage, the person must recognize only the color in which 24 neutral words of different colors appear sequentially on the screen and press the correct key.The third stage involves the most demanding task: words with color names written in different colors are displayed in sequence on the screen (for ex., the word "red" may be written in blue).The person is asked to focus on the color in which the word is written, not what the word says, and press the correct button | ClinicalTrials.gov |
| Primary | Functional near-infrared spectroscopy (fNIRS) | Baseline and 8 weeks | Changes in blood flow in the prefrontal cortex related to executive functions will be assessed using functional near-infrared spectroscopy during a verbal fluency task. During the application, a total of 18 optodes will be placed on the dorsolateral prefrontal cortex (DLPFC). Each source/detector pair will be placed approximately 3 centimeters apart in accordance with the EEG 10-20 system. These optodes will be arranged into 24 channels using a soft neoprene cap. The phonemic verbal fluency test will be administered while the individual is wearing the cap, and data from the measurement during the test will be collected using the fNIRS control box and the connected computer. Thus, while the phonemic verbal fluency test is being administered, changes in the concentration of oxyhemoglobin and deoxyhemoglobin in the prefrontal cortex will be recorded using the fNIRS device. | ClinicalTrials.gov |
| Primary | Verbal fluency test | Baseline and 8 weeks | This test is used to evaluate various executive functions such as attention, semantic memory, information processing speed, task initiation, complex attention, and inhibition of inappropriate responses. The headset will be placed on the individual's head and the optode placement will be adjusted. Recording will then be performed using fNIRS, and a block design consisting of a total of three blocks for the letters 'K, A, S' will be used during the test. Each block covers a total of 140 seconds, consisting of a 10-second pre-rest period, a 60-second activation period, and a 70-second post-rest period. During the activation period, participants will be asked to generate as many words as possible beginning with a specific initial letter. Words should not be proper nouns, repetitions, or numbers. Digital recordings will be made, and the words spoken, their times of utterance, the number of incorrectly spoken words, and the number of repeated words will be recorded. The phonemic fluency sc | ClinicalTrials.gov |
| Primary | Brain-Derived Neurotrophic Factor | Baseline and 8 weeks | Blood samples will be collected in biochemistry tubes before the first session and after the final session of the 8-week intervention. After 10 minutes of centrifugation, serum will be obtained and stored at -80°C until analysis. BDNF, a key neurotrophic factor for neuronal survival, differentiation, and synaptic plasticity, will be measured using the Human Free BDNF Quantikine ELISA Kit (R\&D Systems). The method is based on a sandwich ELISA principle to quantify serum BDNF levels. Venous blood is allowed to clot for 30-60 minutes, centrifuged at 1500-3000 rpm for 10-15 minutes, and stored at -80°C. Before analysis, samples are thawed and processed according to the kit protocol. After incubation, washing, and substrate steps, absorbance is read at 450 nm, and BDNF concentration is calculated from the standard curve. Duplicate measurements are recommended for reliability. | ClinicalTrials.gov |
| Secondary | Respiratory muscle strength | Baseline and 8 weeks | The maximum inspiratory MIP and MEP of the respiratory muscles will be measured using an oral pressure measurement device. Oral pressure measurement for MIP and MEP is a valid and reliable method for assessing respiratory function according to the ATS/ERS protocol. For MIP measurement, the individual is asked to perform a maximum expiration, followed by a maximum inspiration with a nose clip in place, and to hold this for 1-3 seconds. MIP measurement is performed as 3 repeated measurements with no more than a 10% difference between them. The highest value obtained is recorded. For MEP measurement, the individual is asked to perform a maximum inspiration and then, with a nose clip attached, perform the maximum possible inspiration and hold it for 1-3 seconds. Three measurements are taken, with no more than a 10% difference between them. The highest value measured is recorded. To prevent infection risk, single-use, individual mouthpieces and filters will be used during measurement. | ClinicalTrials.gov |
| Secondary | Respiratory muscle endurance | Baseline and 8 weeks | Respiratory muscle strength index (S-index) and peak inspiratory flow rate (PIF) using the dynamic method will be assessed using the portable POWERbreathe K5 device (POWERbreathe K5, HaB International Ltd, Warwickshire, UK). During two distinct phases of the assessment session, patients will perform at least ten consecutive speed-dependent maneuvers (with 4.5 seconds between inspirations). Baseline, warm-up, and post-warm-up assessments will be performed sequentially. During the evaluations, patients will be verbally encouraged to exert maximum effort. At the end of the test, the average and best strength index and PIF values will be examined. | ClinicalTrials.gov |
| Secondary | Respiratory function test | Baseline and 8 weeks | A spirometry test (using the Cosmed Pony FX device) will be performed and evaluated in accordance with the acceptability criteria of the ERS/ATS. The individual's informations are entered into the spirometer device. After the person's nose is closed with a clip, they are asked to place the mouthpiece of the spirometer so that there is no gap around the corners of their mouth. Participants will be given a few practice runs before the test. The first test will be a forced vital capacity measurement. First, the person is asked to take a strong deep breath. After maximal inspiration, the person is asked to exhale forcefully and rapidly until all the air in their lungs is expelled, for as long as possible, and then take another deep inspiration. The test results will determine the measured, predicted, and % predicted values. To minimize infection risk, single-use, individual mouthpieces and filters will be used. | ClinicalTrials.gov |
| Secondary | Increasing Speed Shuttle Walk Test | Baseline and 8 weeks | This test assesses maximal capacity with symptom limitation. There is a good correlation between the increasing pace shuttle walk test and the KPET. During the test, the individual is asked to walk between two cones placed 10 meters apart at an increasing speed for 12 minutes. Each 10-meter distance is defined as one shuttle. The test continues until the individual's heart rate reaches 85% of the expected maximum heart rate, until they are unable to continue the test due to shortness of breath symptoms, or until they complete the test. The main measurement of the test is the walking distance. The minimum clinically meaningful value of the test has been found to be 48 meters. The first and last days of treatment will be evaluated. | ClinicalTrials.gov |
| Secondary | Biochemical analyses: Oxidative Stress | Baseline and 8 weeks | Blood samples will be collected before the first and after the final session of the 8-week treatment. After centrifugation, serum will be obtained and stored at -80°C until analysis. Total Antioxidant Status (TAS) and Total Oxidant Status (TOS) will be measured using Rel Assay Diagnostics kits. TAS reflects the overall antioxidant capacity, based on suppression of color formation in a Fenton-type reaction, and results are expressed as mmol Trolox equiv/L. TOS measures the total oxidant load through oxidation of Fe²⁺ to Fe³⁺, which forms a purple-red complex with xylenol orange; results are expressed as µmol H₂O₂ equiv/L. For both assays, thawed serum, standards, and reagents are pipetted into microplates, incubated, and absorbance is read at 660 nm (TAS) or 560 nm (TOS). The Oxidative Stress Index (OSI) will be calculated as TOS/TAS × 100. | ClinicalTrials.gov |
| Secondary | Daytime Sleepiness Assessment: Epworth Sleepiness Scale (ESS) | Baseline and 8 weeks | The Turkish version will be used to assess individuals' sleepiness during the day. This scale consists of a total of 8 questions, and the maximum possible score is 24. A score of 0-5 is considered normal, 6-10 is normal but indicates increased daytime sleepiness, 11-12 indicates increased but mild daytime sleepiness, 13-15 indicates increased moderate daytime sleepiness, and 16-24 indicates increased severe daytime sleepiness. The first and last days of treatment will be evaluated. | ClinicalTrials.gov |
| Secondary | Sleep quality: Actigraphy | Baseline and 8 weeks | An actigraph is a small, lightweight, watch-like device that can be worn on the wrist. It is non-invasive and continuously records an individual's movement and activity to determine sleep and wakefulness periods. These devices, which can record activity for varying periods depending on the capacity of their micro-sensors, are used in conjunction with sleep diaries to assess sleep patterns and quality (sleep stages, sleep onset latency, total sleep time, number of nighttime awakenings). In our study, we will use the ActiGraph GT3X-BT, a 3-axis accelerometer. Participants will be asked to wear the actigraphy device on the non-dominant wrist for 3 nights (2 weekdays and 1 weekend day) during sleep and to keep a sleep diary. They will be asked to record the times they put on and take off the device, as well as their bedtime, in their sleep diaries. | ClinicalTrials.gov |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | Baseline and 8 weeks | The Turkish version will be used to assess individuals' sleep quality over the past month. The questionnaire consists of 24 questions, 19 of which are answered by the person administering the questionnaire, and the other 5 are answered by someone sharing the same room with the respondent, if applicable. These 5 questions are not included in the calculation of the survey score. The questions in the survey assess the individual's sleep quality, habitual sleep efficiency, sleep latency and duration, sleep medication use, sleep disorder, and daytime dysfunction in 7 categories. The questionnaire is scored on a scale of 0-21, and a score greater than 5 indicates poor sleep quality. | ClinicalTrials.gov |
| Secondary | Anxiety and depression: Hospital Anxiety and Depression Scale (HADS): | Baseline and 8 weeks | The Hospital Anxiety and Depression Scale (HADS), developed by Zigmond and Snaith, was used to assess patients' depression and anxiety levels within the hospital. The HADS scale, which has also been validated and tested for reliability in Turkish, consists of a total of 14 items, with 7 questions assessing anxiety and 7 assessing depression. Each question is scored from 0 to 3 according to the answer given, and as the total score increases, the severity of depression and anxiety also increases. Each is evaluated on a scale of 21 points, with a cutoff value of 7 being normal, 8-10 being mild, 11-14 being moderate, and 15 or above being severe. | ClinicalTrials.gov |
| Secondary | Fatigue Severity Scale | Baseline and 8 weeks | The Turkish version will be used to determine the individual's fatigue level over the past week. The scale consists of a total of 9 questions and has a Likert-type scoring system where each question can be scored from 1 to 7. A score of 7 indicates that the individual strongly agrees, while a score of 1 indicates that they strongly disagree. The total score is calculated by dividing the total points by 9. A result of \<2.8 indicates no fatigue, while a result of \>6.1 indicates severe fatigue. | ClinicalTrials.gov |
| Secondary | Quality of life assessment: Functional Outcomes of Sleep Questionnaire (FOSQ) | Baseline and 8 weeks | The Turkish adaptation will be used to assess the individual's OUAS-specific quality of life. The questionnaire consists of 26 questions, including 7 items assessing attention level, 9 items assessing activity level, 2 items assessing social outcomes, and 8 items assessing overall efficiency. Subgroup scores are calculated between 0 and 4, and the total score that can be obtained from the questionnaire is between 4 and 16. The lower the score, the greater the dysfunction. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)